search
Back to results

Artificial Intelligence Assisted Insulin Titration System (iNCDSS)

Primary Purpose

Type 2 Diabetes

Status
Completed
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
AI assisted insulin system
Physician based insulin regime
Sponsored by
Shanghai Zhongshan Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Men or women aged 18-75 years old;
  • Subjects who had been diagnosed with type 2 diabetes;
  • Subjects who are on treatment with insulin for at least 3 months;
  • HbA1c: 7.0%-11.0%.

Exclusion Criteria:

  • Subjects with acute complications of diabetes such as ketoacidosis or hyperglycemic hyperosmolar state;
  • Subjects who change the insulin regimens during hospitalization;
  • BMI ≥ 45kg/m2;
  • Women who are pregnant or nursing;
  • Subjects with severe cardiac, hepatic, renal or general diseases;
  • Subjects with psychiatric disorders or impaired cognitive function;
  • Subjects with severe edema, infections or peripheral circulation disorders;
  • Patients treated with surgery during hospitalization;
  • Subjects that are, in the judgement of the investigator, unlikely to comply with the protocol.

Sites / Locations

  • 180 Fenglin Road

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

AI Group

Control Group

Arm Description

Artificial intelligence assisted insulin titration system group

Physicians decided insulin titration group

Outcomes

Primary Outcome Measures

Proportion of time in target range
The well-controlled blood glucose level is defined as the time of sensor glucose measurements in targeted range (3.9-10 mmol/L)

Secondary Outcome Measures

Proportion of time in which the blood glucose level is over 10 mmol/L
The poor control of blood glucose level is defined as greater than 10 mmol/L
Proportion of time in which the blood glucose level is below 3.9 mmol/L
The hypoglycemia is defined as blood glucose level less than 3.9mmol/L
Total insulin dose
The total insulin dose is defined as daily insulin dose

Full Information

First Posted
August 10, 2019
Last Updated
July 24, 2020
Sponsor
Shanghai Zhongshan Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT04053959
Brief Title
Artificial Intelligence Assisted Insulin Titration System
Acronym
iNCDSS
Official Title
A Study to Assess the Effect and Safety of Artificial Intelligence Assisted Insulin Titration System on Glucose Control in Type 2 Diabetes Mellitus Patients: A Single-center, Open-labeled, Parallel, Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
July 2020
Overall Recruitment Status
Completed
Study Start Date
September 27, 2019 (Actual)
Primary Completion Date
January 22, 2020 (Actual)
Study Completion Date
April 15, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Shanghai Zhongshan Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a single-center, open-labeled, parallel group, randomized controlled trial to access the effect and safety of the Artificial Intelligence Assisted Insulin Titration System in patients with Type 2 Diabetes Mellitus.
Detailed Description
The study enrolls 44 patients with Type 2 Diabetes in Zhongshan Hospital who are on treatment with insulin for at least 3 months. They are randomly allocated into 2 groups at a ratio of 1:1 after screening for the inclusion and exclusion criteria. Patients in the Intervention group receive insulin regimen set by the AI assisted system and patients in Control group receive insulin regimen set by physicians. This study will be conducted in the Department of Endocrinology, Zhongshan Hospital,Fudan University and consist of a 7-day intervention period. Patient allocation will be stratified by HbA1c, BMI and previous total insulin doses.The primary endpoint is the percentage of time of sensor glucose measurements in targeted range (3.9-10 mmol/L) during the 7-days trial period.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
A paralle group, randomized, controlled study to assess the effect and safety of artificial intelligence assisted insulin dosage titration system on glucose control in type 2 diabetic patients
Masking
ParticipantOutcomes Assessor
Masking Description
The research assistants who collect study outcome data will be masked to participants' intervention assignment. In addition, the adjudicators for end-points will not be aware of study-group assignments.
Allocation
Randomized
Enrollment
46 (Actual)

8. Arms, Groups, and Interventions

Arm Title
AI Group
Arm Type
Experimental
Arm Description
Artificial intelligence assisted insulin titration system group
Arm Title
Control Group
Arm Type
Active Comparator
Arm Description
Physicians decided insulin titration group
Intervention Type
Drug
Intervention Name(s)
AI assisted insulin system
Intervention Description
The patients receive the insulin regime set by AI assisted insulin titration system
Intervention Type
Drug
Intervention Name(s)
Physician based insulin regime
Intervention Description
Patients receive the insulin regime recommended by physicians
Primary Outcome Measure Information:
Title
Proportion of time in target range
Description
The well-controlled blood glucose level is defined as the time of sensor glucose measurements in targeted range (3.9-10 mmol/L)
Time Frame
During 7-day intervention
Secondary Outcome Measure Information:
Title
Proportion of time in which the blood glucose level is over 10 mmol/L
Description
The poor control of blood glucose level is defined as greater than 10 mmol/L
Time Frame
During 7-day intervention
Title
Proportion of time in which the blood glucose level is below 3.9 mmol/L
Description
The hypoglycemia is defined as blood glucose level less than 3.9mmol/L
Time Frame
During 7-day intervention
Title
Total insulin dose
Description
The total insulin dose is defined as daily insulin dose
Time Frame
Each day during 7-day intervention

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Men or women aged 18-75 years old; Subjects who had been diagnosed with type 2 diabetes; Subjects who are on treatment with insulin for at least 3 months; HbA1c: 7.0%-11.0%. Exclusion Criteria: Subjects with acute complications of diabetes such as ketoacidosis or hyperglycemic hyperosmolar state; Subjects who change the insulin regimens during hospitalization; BMI ≥ 45kg/m2; Women who are pregnant or nursing; Subjects with severe cardiac, hepatic, renal or general diseases; Subjects with psychiatric disorders or impaired cognitive function; Subjects with severe edema, infections or peripheral circulation disorders; Patients treated with surgery during hospitalization; Subjects that are, in the judgement of the investigator, unlikely to comply with the protocol.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Xiaoying Li, MD
Organizational Affiliation
Fudan University
Official's Role
Principal Investigator
Facility Information:
Facility Name
180 Fenglin Road
City
Shanghai
ZIP/Postal Code
200032
Country
China

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
24002281
Citation
Xu Y, Wang L, He J, Bi Y, Li M, Wang T, Wang L, Jiang Y, Dai M, Lu J, Xu M, Li Y, Hu N, Li J, Mi S, Chen CS, Li G, Mu Y, Zhao J, Kong L, Chen J, Lai S, Wang W, Zhao W, Ning G; 2010 China Noncommunicable Disease Surveillance Group. Prevalence and control of diabetes in Chinese adults. JAMA. 2013 Sep 4;310(9):948-59. doi: 10.1001/jama.2013.168118.
Results Reference
background
PubMed Identifier
25848699
Citation
Wang T, Xu Y, Xu M, Wang W, Bi Y, Lu J, Dai M, Zhang D, Ding L, Xu B, Sun J, Zhao W, Jiang Y, Wang L, Li Y, Zhang M, Lai S, Wang L, Ning G. Awareness, treatment and control of cardiometabolic disorders in Chinese adults with diabetes: a national representative population study. Cardiovasc Diabetol. 2015 Feb 26;14:28. doi: 10.1186/s12933-015-0191-6.
Results Reference
background
PubMed Identifier
23800082
Citation
Ji LN, Lu JM, Guo XH, Yang WY, Weng JP, Jia WP, Zou DJ, Zhou ZG, Yu DM, Liu J, Shan ZY, Yang YZ, Hu RM, Zhu DL, Yang LY, Chen L, Zhao ZG, Li QF, Tian HM, Ji QH, Liu J, Ge JP, Shi LX, Xu YC. Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables. BMC Public Health. 2013 Jun 21;13:602. doi: 10.1186/1471-2458-13-602.
Results Reference
background
PubMed Identifier
15920040
Citation
Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R; ATLANTUS Study Group. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care. 2005 Jun;28(6):1282-8. doi: 10.2337/diacare.28.6.1282.
Results Reference
background
PubMed Identifier
19854333
Citation
Oyer DS, Shepherd MD, Coulter FC, Bhargava A, Brett J, Chu PL, Trippe BS; INITIATEplus Study Group. A(1c) control in a primary care setting: self-titrating an insulin analog pre-mix (INITIATEplus trial). Am J Med. 2009 Nov;122(11):1043-9. doi: 10.1016/j.amjmed.2008.12.026.
Results Reference
background
PubMed Identifier
26816605
Citation
Yang W, Zhu L, Meng B, Liu Y, Wang W, Ye S, Sun L, Miao H, Guo L, Wang Z, Lv X, Li Q, Ji Q, Zhao W, Yang G. Subject-driven titration of biphasic insulin aspart 30 twice daily is non-inferior to investigator-driven titration in Chinese patients with type 2 diabetes inadequately controlled with premixed human insulin: A randomized, open-label, parallel-group, multicenter trial. J Diabetes Investig. 2016 Jan;7(1):85-93. doi: 10.1111/jdi.12364. Epub 2015 May 25.
Results Reference
background
PubMed Identifier
18411384
Citation
Harris S, Yale JF, Dempsey E, Gerstein H. Can family physicians help patients initiate basal insulin therapy successfully?: randomized trial of patient-titrated insulin glargine compared with standard oral therapy: lessons for family practice from the Canadian INSIGHT trial. Can Fam Physician. 2008 Apr;54(4):550-8.
Results Reference
background
PubMed Identifier
28539087
Citation
Rigla M, Garcia-Saez G, Pons B, Hernando ME. Artificial Intelligence Methodologies and Their Application to Diabetes. J Diabetes Sci Technol. 2018 Mar;12(2):303-310. doi: 10.1177/1932296817710475. Epub 2017 May 25.
Results Reference
background
PubMed Identifier
30269984
Citation
Ashrafzadeh S, Hamdy O. Patient-Driven Diabetes Care of the Future in the Technology Era. Cell Metab. 2019 Mar 5;29(3):564-575. doi: 10.1016/j.cmet.2018.09.005. Epub 2018 Sep 27.
Results Reference
background
PubMed Identifier
27836235
Citation
Thabit H, Hartnell S, Allen JM, Lake A, Wilinska ME, Ruan Y, Evans ML, Coll AP, Hovorka R. Closed-loop insulin delivery in inpatients with type 2 diabetes: a randomised, parallel-group trial. Lancet Diabetes Endocrinol. 2017 Feb;5(2):117-124. doi: 10.1016/S2213-8587(16)30280-7. Epub 2016 Nov 9.
Results Reference
background
PubMed Identifier
29940126
Citation
Bally L, Thabit H, Hartnell S, Andereggen E, Ruan Y, Wilinska ME, Evans ML, Wertli MM, Coll AP, Stettler C, Hovorka R. Closed-Loop Insulin Delivery for Glycemic Control in Noncritical Care. N Engl J Med. 2018 Aug 9;379(6):547-556. doi: 10.1056/NEJMoa1805233. Epub 2018 Jun 25.
Results Reference
background

Learn more about this trial

Artificial Intelligence Assisted Insulin Titration System

We'll reach out to this number within 24 hrs